Clinical Trials
94 trialsNCT06391099 2026-05-26
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Suspended
NCT07405086 2026-05-22
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT07468903 2026-05-22
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase NA Recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT06733350 2026-05-14
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
Roswell Park Cancer Institute
Phase 4 Recruiting
NCT05689021 2026-05-11
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT07128680 2026-05-11
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07578025 2026-05-11
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07087860 2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT04134260 2026-05-07
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT05946213 2026-05-07
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT05521698 2026-05-05
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Recruiting
NCT06616155 2026-05-05
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT04513717 2026-05-04
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05053152 2026-05-04
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07037004 2026-05-04
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07097142 2026-05-04
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT03575611 2026-04-15
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05960578 2026-04-14
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT06389786 2026-04-06
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Mayo Clinic
Phase NA Recruiting
NCT07510334 2026-04-03
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Not yet recruiting
NCT06526299 2026-03-24
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT04190446 2026-03-16
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04788277 2026-03-13
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
Thomas Jefferson University
Recruiting
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07025369 2026-03-13
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
Phase 2 Recruiting
NCT04706481 2026-03-12
Archival of Human Biological Samples in CU-Med Biobank
Chinese University of Hong Kong
Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06349642 2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
NCT07466498 2026-03-12
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
University of Washington
Phase 2 Not yet recruiting
NCT07164027 2026-03-10
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06330805 2026-03-09
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06432036 2026-03-06
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT05045066 2026-03-02
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT06630416 2026-02-24
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT07377006 2026-02-18
Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase NA Not yet recruiting
NCT04489719 2026-02-17
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
Recruiting
NCT06236139 2026-02-17
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT06625034 2026-02-10
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
Phase 3 Recruiting